髓系细胞触发受体2（TREM2）在急慢性肝病中的作用

崔馨月, 孙全昊, 郑丽红, 王海强

PDF(596 KB)
中国高校科技期刊信息汇聚平台
PDF(596 KB)
临床肝胆病杂志 ›› 2025, Vol. 41 ›› Issue (2) : 383-388. DOI: 10.12449/JCH250228
综述

髓系细胞触发受体2（TREM2）在急慢性肝病中的作用

作者信息 +

Role of triggering receptor expressed on myeloid cells 2 in acute and chronic liver diseases

Author information +
History +

摘要

在肝脏中髓系细胞触发受体2（TREM2）表达于常驻非实质细胞，参与肝脏炎症、免疫调控等病理过程。近年来，TREM2在急慢性肝病研究领域中受到关注，且越来越多的研究表明TREM2是治疗急慢性肝病的潜在靶点，然而其在急慢性肝病中的作用机制缺乏系统性的总结。本文综述了TREM2在急慢性肝病中调控作用的最新研究进展，以期为临床防治急慢性肝病提供新思路。

Abstract

Triggering receptor expressed on myeloid cells 2 （TREM2） is expressed in resident non-parenchymal cells （NPCs） and is involved in various pathological processes including liver inflammation and immunoregulation. In recent years， TREM2 has attracted attention in the field of acute and chronic liver diseases， and more and more studies have shown that TREM2 is a potential target for the treatment of acute and chronic liver diseases； however， there is a lack of systematic summary for the mechanism of action of TREM2 in acute and chronic liver diseases. Therefore， this article reviews the latest research advances in the regulatory role of TREM2 in acute and chronic liver diseases， in order to provide new ideas for the clinical prevention and treatment of acute and chronic liver diseases.

关键词

髓系细胞触发受体2 / 肝疾病 / 病理过程

Key words

Triggering Receptor Expressed on Myeloid Cells 2 / Liver Diseases / Pathologic Processes

引用本文

EndNote

Ris (Procite)

Bibtex

导出引用
崔馨月 , 孙全昊 , 郑丽红 , 等. 髓系细胞触发受体2（TREM2）在急慢性肝病中的作用. 临床肝胆病杂志. 2025, 41(2): 383-388 https://doi.org/10.12449/JCH250228
Xinyue CUI, Quanhao SUN, Lihong ZHENG, et al. Role of triggering receptor expressed on myeloid cells 2 in acute and chronic liver diseases[J]. Journal of Clinical Hepatol. 2025, 41(2): 383-388 https://doi.org/10.12449/JCH250228

参考文献

列表( 原文顺序 | 文献年度倒序 | 文中引用次数倒序 ) 可视化分析
1
COLONNA M. The biology of TREM receptors[J]. Nat Rev Immunol, 2023, 23(9): 580-594. DOI: 10.1038/s41577-023-00837-1 .
本文引用 [1]
2
ULLAND TK, SONG WM, HUANG SC, et al. TREM2 maintains microglial metabolic fitness in Alzheimer’s disease[J]. Cell, 2017, 170(4): 649-663. e13. DOI: 10.1016/j.cell.2017.07.023 .
本文引用 [1]
3
SUN HF, FENG JG, TANG LL. Function of TREM1 and TREM2 in liver-related diseases[J]. Cells, 2020, 9(12): 2626. DOI: 10.3390/cells9122626 .
本文引用 [1]
4
HENDRIKX T, PORSCH F, KISS MG, et al. Soluble TREM2 levels reflect the recruitment and expansion of TREM2+ macrophages that localize to fibrotic areas and limit NASH[J]. J Hepatol, 2022, 77(5): 1373-1385. DOI: 10.1016/j.jhep.2022.06.004 .
本文引用 [2]
5
INDIRA CHANDRAN V, WERNBERG CW, LAURIDSEN MM, et al. Circulating TREM2 as a noninvasive diagnostic biomarker for NASH in patients with elevated liver stiffness[J]. Hepatology, 2023, 77(2): 558-572. DOI: 10.1002/hep.32620 .
本文引用 [1]
6
PERUGORRIA MJ, ESPARZA-BAQUER A, OAKLEY F, et al. Non-parenchymal TREM-2 protects the liver from immune-mediated hepatocellular damage[J]. Gut, 2019, 68(3): 533-546. DOI: 10.1136/gutjnl-2017-314107 .
本文引用 [1]
7
XIONG XL, KUANG H, ANSARI S, et al. Landscape of intercellular crosstalk in healthy and NASH liver revealed by single-cell secretome gene analysis[J]. Mol Cell, 2019, 75(3): 644-660. e5. DOI: 10.1016/j.molcel.2019.07.028 .
本文引用 [1]
8
GOVAERE O, COCKELL S, TINIAKOS D, et al. Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis[J]. Sci Transl Med, 2020, 12(572): eaba4448. DOI: 10.1126/scitranslmed.aba4448 .
本文引用 [1]
9
ESPARZA-BAQUER A, LABIANO I, SHARIF O, et al. TREM-2 defends the liver against hepatocellular carcinoma through multifactorial protective mechanisms[J]. Gut, 2021, 70(7): 1345-1361. DOI: 10.1136/gutjnl-2019-319227 .
本文引用 [3]
10
MOLGORA M, ESAULOVA E, VERMI W, et al. TREM2 modulation remodels the tumor myeloid landscape enhancing anti-PD-1 immunotherapy[J]. Cell, 2020, 182(4): 886-900. e17. DOI: 10.1016/j.cell.2020.07.013 .
本文引用 [2]
11
HAN S, LI XD, XIA N, et al. Myeloid Trem2 dynamically regulates the induction and resolution of hepatic ischemia-reperfusion injury inflammation[J]. Int J Mol Sci, 2023, 24(7): 6348. DOI: 10.3390/ijms24076348 .
本文引用 [2]
12
LANIER LL, CORLISS BC, WU J, et al. Immunoreceptor DAP12 bearing a tyrosine-based activation motif is involved in activating NK cells[J]. Nature, 1998, 391(6668): 703-707. DOI: 10.1038/35642 .
本文引用 [1]
13
ULLAND TK, COLONNA M. TREM2—a key player in microglial biology and Alzheimer disease[J]. Nat Rev Neurol, 2018, 14: 667-675. DOI: 10.1038/s41582-018-0072-1 .
本文引用 [1]
14
PENG QS, MALHOTRA S, TORCHIA JA, et al. TREM2- and DAP12-dependent activation of PI3K requires DAP10 and is inhibited by SHIP1[J]. Sci Signal, 2010, 3(122): ra38. DOI: 10.1126/scisignal.2000500 .
本文引用 [2]
15
KOBER DL, BRETT TJ. TREM2-ligand interactions in health and disease[J]. J Mol Biol, 2017, 429(11): 1607-1629. DOI: 10.1016/j.jmb.2017.04.004 .
本文引用 [1]
16
HAMERMAN JA, JARJOURA JR, HUMPHREY MB, et al. Cutting edge: Inhibition of TLR and FcR responses in macrophages by triggering receptor expressed on myeloid cells (TREM)-2 and DAP12[J]. J Immunol, 2006, 177(4): 2051-2055. DOI: 10.4049/jimmunol.177.4.2051 .
本文引用 [1]
17
PALONEVA J, MANDELIN J, KIIALAINEN A, et al. DAP12/TREM2 deficiency results in impaired osteoclast differentiation and osteoporotic features[J]. J Exp Med, 2003, 198(4): 669-675. DOI: 10.1084/jem.20030027 .
本文引用 [1]
18
BHARADWAJ S, GROZA Y, MIERZWICKA JM, et al. Current understanding on TREM-2 molecular biology and physiopathological functions[J]. Int Immunopharmacol, 2024, 134: 112042. DOI: 10.1016/j.intimp.2024.112042 .
本文引用 [1]
19
KHANTAKOVA D, BRIOSCHI S, MOLGORA M. Exploring the impact of TREM2 in tumor-associated macrophages[J]. Vaccines (Basel), 2022, 10(6): 943. DOI: 10.3390/vaccines10060943 .
本文引用 [3]
20
FEUERBACH D, SCHINDLER P, BARSKE C, et al. ADAM17 is the main sheddase for the generation of human triggering receptor expressed in myeloid cells (hTREM2) ectodomain and cleaves TREM2 after Histidine 157[J]. Neurosci Lett, 2017, 660: 109-114. DOI: 10.1016/j.neulet.2017.09.034 .
本文引用 [1]
21
NI M, ZHANG J, SOSA R, et al. T-cell immunoglobulin and mucin domain-containing protein-4 is critical for kupffer cell homeostatic function in the activation and resolution of liver ischemia reperfusion injury[J]. Hepatology, 2021, 74(4): 2118-2132. DOI: 10.1002/hep.31906 .
本文引用 [1]
22
POWELL EE, WONG VW, RINELLA M. Non-alcoholic fatty liver disease[J]. Lancet, 2021, 397(10290): 2212-2224. DOI: 10.1016/S0140-6736(20)32511-3 .
本文引用 [1]
23
LEUNG PB, DAVIS AM, KUMAR S. Diagnosis and management of nonalcoholic fatty liver disease[J]. JAMA, 2023, 330(17): 1687-1688. DOI: 10.1001/jama.2023.17935 .
本文引用 [1]
24
LIEBOLD I, MEYER S, HEINE M, et al. TREM2 regulates the removal of apoptotic cells and inflammatory processes during the progression of NAFLD[J]. Cells, 2023, 12(3): 341. DOI: 10.3390/cells12030341 .
本文引用 [4]
25
DAWS MR, SULLAM PM, NIEMI EC, et al. Pattern recognition by TREM-2: Binding of anionic ligands[J]. J Immunol, 2003, 171(2): 594-599. DOI: 10.4049/jimmunol.171.2.594 .
本文引用 [1]
26
TURNBULL IR, GILFILLAN S, CELLA M, et al. Cutting edge: TREM-2 attenuates macrophage activation[J]. J Immunol, 2006, 177(6): 3520-3524. DOI: 10.4049/jimmunol.177.6.3520 .
本文引用 [1]
27
WANG XC, HE QF, ZHOU CL, et al. Prolonged hypernutrition impairs TREM2-dependent efferocytosis to license chronic liver inflammation and NASH development[J]. Immunity, 2023, 56(1): 58-77. e11. DOI: 10.1016/j.immuni.2022.11.013 .
本文引用 [1]
28
HOU JC, ZHANG J, CUI P, et al. TREM2 sustains macrophage-hepatocyte metabolic coordination in nonalcoholic fatty liver disease and sepsis[J]. J Clin Invest, 2021, 131(4): e135197. DOI: 10.1172/JCI135197 .
本文引用 [1]
29
ZHOU LK, QIU XX, MENG ZY, et al. Hepatic danger signaling triggers TREM2+ macrophage induction and drives steatohepatitis via MS4A7-dependent inflammasome activation[J]. Sci Transl Med, 2024, 16(738): eadk1866. DOI: 10.1126/scitranslmed.adk1866 .
本文引用 [1]
30
WOOLBRIGHT BL, JAESCHKE H. Inflammation and cell death during cholestasis: The evolving role of bile acids[J]. Gene Expr, 2019, 19(3): 215-228. DOI: 10.3727/105221619X15614873062730 .
本文引用 [1]
31
de VRIES E, BEUERS U. Management of cholestatic disease in 2017[J]. Liver Int, 2017, 37(): 123-129. DOI: 10.1111/liv.13306 .
本文引用 [1] 摘要
Suppl 1
32
LABIANO I, AGIRRE-LIZASO A, OLAIZOLA P, et al. TREM-2 plays a protective role in cholestasis by acting as a negative regulator of inflammation[J]. J Hepatol, 2022, 77(4): 991-1004. DOI: 10.1016/j.jhep.2022.05.044 .
本文引用 [3]
33
IREDALE JP. Models of liver fibrosis: Exploring the dynamic nature of inflammation and repair in a solid organ[J]. J Clin Invest, 2007, 117(3): 539-548. DOI: 10.1172/JCI30542 .
本文引用 [1]
34
KISSELEVA T, BRENNER D. Molecular and cellular mechanisms of liver fibrosis and its regression[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(3): 151-166. DOI: 10.1038/s41575-020-00372-7 .
本文引用 [1]
35
RAMACHANDRAN P, DOBIE R, WILSON-KANAMORI JR, et al. Resolving the fibrotic niche of human liver cirrhosis at single-cell level[J]. Nature, 2019, 575(7783): 512-518. DOI: 10.1038/s41586-019-1631-3 .
本文引用 [1]
36
ZHU DD, HUANG M, SHEN P, et al. TREM2 expression promotes liver and peritoneal M2 macrophage polarization in mice infected with Schistosoma japonicum[J]. J Cell Mol Med, 2023, 27(15): 2261-2269. DOI: 10.1111/jcmm.17842 .
本文引用 [2]
37
YE ZH, HUANG SG, ZHANG YX, et al. Galectins, eosinophiles, and macrophages may contribute to Schistosoma japonicum egg-induced immunopathology in a mouse model[J]. Front Immunol, 2020, 11: 146. DOI: 10.3389/fimmu.2020.00146 .
本文引用 [1]
38
SHAN S, CHAO S, LIU Z, et al. TREM2 protects against inflammation by regulating the release of mito-DAMPs from hepatocytes during liver fibrosis[J]. Free Radic Biol Med, 2024, 220: 154-165. DOI: 10.1016/j.freeradbiomed.2024.05.004 .
本文引用 [1]
39
MANTOVANI A, MARCHESI F, MALESCI A, et al. Tumour-associated macrophages as treatment targets in oncology[J]. Nat Rev Clin Oncol, 2017, 14(7): 399-416. DOI: 10.1038/nrclinonc.2016.217 .
本文引用 [1]
40
DENARDO DG, RUFFELL B. Macrophages as regulators of tumour immunity and immunotherapy[J]. Nat Rev Immunol, 2019, 19(6): 369-382. DOI: 10.1038/s41577-019-0127-6 .
本文引用 [1]
41
CASSETTA L, POLLARD JW. Targeting macrophages: Therapeutic approaches in cancer[J]. Nat Rev Drug Discov, 2018, 17(12): 887-904. DOI: 10.1038/nrd.2018.169 .
本文引用 [1]
42
WANG QY, ZHENG K, TAN D, et al. TREM2 knockdown improves the therapeutic effect of PD-1 blockade in hepatocellular carcinoma[J]. Biochem Biophys Res Commun, 2022, 636(Pt 1): 140-146. DOI: 10.1016/j.bbrc.2022.10.079 .
本文引用 [1]
43
ZHOU LS, WANG ML, GUO HR, et al. Integrated analysis highlights the immunosuppressive role of TREM2+ macrophages in hepatocellular carcinoma[J]. Front Immunol, 2022, 13: 848367. DOI: 10.3389/fimmu.2022.848367 .
本文引用 [1]
44
VOGEL A, MEYER T, SAPISOCHIN G, et al. Hepatocellular carcinoma[J]. Lancet, 2022, 400(10360): 1345-1362. DOI: 10.1016/S0140-6736(22)01200-4 .
本文引用 [1]
45
PALMER DH, MALAGARI K, KULIK LM. Role of locoregional therapies in the wake of systemic therapy[J]. J Hepatol, 2020, 72(2): 277-287. DOI: 10.1016/j.jhep.2019.09.023 .
本文引用 [1]
46
SUN YF, WU L, ZHONG Y, et al. Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma[J]. Cell, 2021, 184(2): 404-421. e16. DOI: 10.1016/j.cell.2020.11.041 .
本文引用 [1]
47
TAN JZ, FAN WZ, LIU T, et al. TREM2+ macrophages suppress CD8+ T-cell infiltration after transarterial chemoembolisation in hepatocellular carcinoma[J]. J Hepatol, 2023, 79(1): 126-140. DOI: 10.1016/j.jhep.2023.02.032 .
本文引用 [1]

作者贡献声明

崔馨月负责文章的构思与设计，论文撰写；孙全昊负责论文修订；郑丽红负责论文修订与审校；王海强负责最终版本修订。

评论

PDF(596 KB)

Accesses

Citation

Detail
段落导航
相关文章
Copyright 中国高校科技期刊信息汇聚平台 2024-2025
技术支持：北京玛格泰克科技发展有限公司
京ICP备05021913号-19

/

〈 〉